| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1056: Molnupiravir for treating COVID-19 |
|
Medicine details |
|
| Medicine name | molnupiravir (Lagevrio®) |
| Formulation | 200 mg hard capsule |
| Reference number | 4689 |
| Indication | Treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness |
| Company | Merck Sharp & Dohme Ltd |
| BNF chapter | Infections |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 11/01/2022 |
| NICE guidance | |